BAUSCH HEALTH COS INC (BHC) Fundamental Analysis & Valuation
NYSE:BHC • CA0717341071
Current stock price
5.35 USD
+0.09 (+1.71%)
At close:
5.35 USD
0 (0%)
After Hours:
This BHC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BHC Profitability Analysis
1.1 Basic Checks
- BHC had positive earnings in the past year.
- BHC had a positive operating cash flow in the past year.
- BHC had negative earnings in 4 of the past 5 years.
- Of the past 5 years BHC 4 years had a positive operating cash flow.
1.2 Ratios
- The Return On Assets of BHC (0.60%) is better than 79.69% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 7.78%, BHC belongs to the top of the industry, outperforming 85.94% of the companies in the same industry.
- BHC had an Average Return On Invested Capital over the past 3 years of 6.89%. This is significantly below the industry average of 13.06%.
- The last Return On Invested Capital (7.78%) for BHC is above the 3 year average (6.89%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROIC | 7.78% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
1.3 Margins
- BHC's Profit Margin of 1.53% is fine compared to the rest of the industry. BHC outperforms 79.69% of its industry peers.
- The Operating Margin of BHC (21.28%) is better than 88.02% of its industry peers.
- In the last couple of years the Operating Margin of BHC has grown nicely.
- BHC's Gross Margin of 70.65% is fine compared to the rest of the industry. BHC outperforms 77.60% of its industry peers.
- In the last couple of years the Gross Margin of BHC has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% |
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
2. BHC Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BHC is still creating some value.
- Compared to 1 year ago, BHC has more shares outstanding
- The number of shares outstanding for BHC has been increased compared to 5 years ago.
- BHC has a better debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of 0.28, we must say that BHC is in the distress zone and has some risk of bankruptcy.
- BHC's Altman-Z score of 0.28 is in line compared to the rest of the industry. BHC outperforms 49.48% of its industry peers.
- BHC has a debt to FCF ratio of 21.00. This is a negative value and a sign of low solvency as BHC would need 21.00 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 21.00, BHC is in the better half of the industry, outperforming 76.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Altman-Z | 0.28 |
ROIC/WACC1.2
WACC6.49%
2.3 Liquidity
- A Current Ratio of 1.47 indicates that BHC should not have too much problems paying its short term obligations.
- BHC's Current ratio of 1.47 is on the low side compared to the rest of the industry. BHC is outperformed by 74.48% of its industry peers.
- A Quick Ratio of 1.08 indicates that BHC should not have too much problems paying its short term obligations.
- BHC's Quick ratio of 1.08 is on the low side compared to the rest of the industry. BHC is outperformed by 77.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 |
3. BHC Growth Analysis
3.1 Past
- BHC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
- BHC shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.13% yearly.
- BHC shows a small growth in Revenue. In the last year, the Revenue has grown by 6.66%.
- The Revenue has been growing slightly by 5.04% on average over the past years.
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
3.2 Future
- The Earnings Per Share is expected to decrease by -1.34% on average over the next years.
- The Revenue is expected to decrease by -0.94% on average over the next years.
EPS Next Y15.65%
EPS Next 2Y3.9%
EPS Next 3Y-5.25%
EPS Next 5Y-1.34%
Revenue Next Year4.48%
Revenue Next 2Y2.16%
Revenue Next 3Y-2.16%
Revenue Next 5Y-0.94%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. BHC Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 1.42 indicates a rather cheap valuation of BHC.
- BHC's Price/Earnings ratio is rather cheap when compared to the industry. BHC is cheaper than 99.48% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 26.91, BHC is valued rather cheaply.
- With a Price/Forward Earnings ratio of 1.23, the valuation of BHC can be described as very cheap.
- Based on the Price/Forward Earnings ratio, BHC is valued cheaper than 98.96% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 23.69. BHC is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.42 | ||
| Fwd PE | 1.23 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BHC indicates a rather cheap valuation: BHC is cheaper than 95.31% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, BHC is valued cheaply inside the industry as 99.48% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2 | ||
| EV/EBITDA | 6.33 |
4.3 Compensation for Growth
- BHC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of BHC may justify a higher PE ratio.
- A cheap valuation may be justified as BHC's earnings are expected to decrease with -5.25% in the coming years.
PEG (NY)0.09
PEG (5Y)N/A
EPS Next 2Y3.9%
EPS Next 3Y-5.25%
5. BHC Dividend Analysis
5.1 Amount
- No dividends for BHC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BHC Fundamentals: All Metrics, Ratios and Statistics
5.35
+0.09 (+1.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-20 2026-02-20/amc
Earnings (Next)04-29 2026-04-29
Inst Owners44.72%
Inst Owner Change0%
Ins Owners11.42%
Ins Owner Change10.2%
Market Cap1.98B
Revenue(TTM)10.27B
Net Income(TTM)157.00M
Analysts48.89
Price Target7.43 (38.88%)
Short Float %2.18%
Short Ratio2.77
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.64%
Min EPS beat(2)-13.87%
Max EPS beat(2)2.59%
EPS beat(4)1
Avg EPS beat(4)-10.87%
Min EPS beat(4)-25.13%
Max EPS beat(4)2.59%
EPS beat(8)3
Avg EPS beat(8)-7.33%
EPS beat(12)6
Avg EPS beat(12)-4.52%
EPS beat(16)7
Avg EPS beat(16)-7.67%
Revenue beat(2)2
Avg Revenue beat(2)1.43%
Min Revenue beat(2)0.64%
Max Revenue beat(2)2.23%
Revenue beat(4)3
Avg Revenue beat(4)0.41%
Min Revenue beat(4)-1.57%
Max Revenue beat(4)2.23%
Revenue beat(8)6
Avg Revenue beat(8)0.66%
Revenue beat(12)9
Avg Revenue beat(12)1.15%
Revenue beat(16)10
Avg Revenue beat(16)0.16%
PT rev (1m)0%
PT rev (3m)0.47%
EPS NQ rev (1m)-6.59%
EPS NQ rev (3m)-6.38%
EPS NY rev (1m)0%
EPS NY rev (3m)1.71%
Revenue NQ rev (1m)-0.78%
Revenue NQ rev (3m)-1.02%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)0.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.42 | ||
| Fwd PE | 1.23 | ||
| P/S | 0.19 | ||
| P/FCF | 2 | ||
| P/OCF | 1.42 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.33 |
EPS(TTM)3.77
EY70.47%
EPS(NY)4.36
Fwd EY81.49%
FCF(TTM)2.68
FCFY50.09%
OCF(TTM)3.78
OCFY70.62%
SpS27.7
BVpS-1.5
TBVpS-44.44
PEG (NY)0.09
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROCE | 9.85% | ||
| ROIC | 7.78% | ||
| ROICexc | 8.27% | ||
| ROICexgc | 34.78% | ||
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% | ||
| FCFM | 9.67% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
ROICexc(3y)7.29%
ROICexc(5y)6.47%
ROICexgc(3y)46.04%
ROICexgc(5y)39.55%
ROCE(3y)8.72%
ROCE(5y)7.82%
ROICexgc growth 3Y6.69%
ROICexgc growth 5Y7.05%
ROICexc growth 3Y16.83%
ROICexc growth 5Y15.41%
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
F-Score6
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Debt/EBITDA | 6.08 | ||
| Cap/Depr | 33.69% | ||
| Cap/Sales | 3.96% | ||
| Interest Coverage | 1.42 | ||
| Cash Conversion | 41.26% | ||
| Profit Quality | 632.48% | ||
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 | ||
| Altman-Z | 0.28 |
F-Score6
WACC6.49%
ROIC/WACC1.2
Cap/Depr(3y)27.35%
Cap/Depr(5y)23.9%
Cap/Sales(3y)3.53%
Cap/Sales(5y)3.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
EPS Next Y15.65%
EPS Next 2Y3.9%
EPS Next 3Y-5.25%
EPS Next 5Y-1.34%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
Revenue Next Year4.48%
Revenue Next 2Y2.16%
Revenue Next 3Y-2.16%
Revenue Next 5Y-0.94%
EBIT growth 1Y17.85%
EBIT growth 3Y16.27%
EBIT growth 5Y10.72%
EBIT Next Year33.3%
EBIT Next 3Y-2.01%
EBIT Next 5Y1.11%
FCF growth 1Y-21%
FCF growth 3YN/A
FCF growth 5Y4.37%
OCF growth 1Y-12.34%
OCF growth 3YN/A
OCF growth 5Y4.73%
BAUSCH HEALTH COS INC / BHC Fundamental Analysis FAQ
What is the ChartMill fundamental rating of BAUSCH HEALTH COS INC (BHC) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BHC.
What is the valuation status of BAUSCH HEALTH COS INC (BHC) stock?
ChartMill assigns a valuation rating of 9 / 10 to BAUSCH HEALTH COS INC (BHC). This can be considered as Undervalued.
What is the profitability of BHC stock?
BAUSCH HEALTH COS INC (BHC) has a profitability rating of 6 / 10.
How financially healthy is BAUSCH HEALTH COS INC?
The financial health rating of BAUSCH HEALTH COS INC (BHC) is 3 / 10.
What is the earnings growth outlook for BAUSCH HEALTH COS INC?
The Earnings per Share (EPS) of BAUSCH HEALTH COS INC (BHC) is expected to grow by 15.65% in the next year.